Vasican

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasican

What is Vasican?

Vasican is a pharmacological treatment primarily utilized in the management of chronic venous insufficiency and related vascular conditions. It belongs to a class of medications known as venotonics and vascular protectors. These agents are designed to influence the tone of the venous walls and improve the overall microcirculation within the body.

Mechanism of Action

The active components in Vasican work by increasing the muscular tone of the veins, which helps to facilitate the return of blood toward the heart. By reducing venous distensibility and stasis, the medication addresses the underlying physiological issues that lead to swelling and discomfort in the extremities. Additionally, Vasican acts on the capillary system to decrease permeability and increase resistance, which helps prevent the leakage of fluids into surrounding tissues.

Primary Uses

Vasican is commonly used to address symptoms associated with venous circulation disorders. These symptoms often include:

  • Heavy Legs: A sensation of weight or fatigue in the lower limbs, particularly after long periods of standing or sitting.
  • Pain and Cramping: Localized discomfort or nocturnal cramps often linked to poor venous return.
  • Edema: Swelling in the ankles and lower legs caused by fluid retention in the tissues.
  • Hemorrhoidal Disease: The treatment of functional symptoms related to acute hemorrhoidal episodes, where vascular protection is required to reduce inflammation and discomfort.

Therapeutic Role

As a systemic treatment, Vasican provides a comprehensive approach to vascular health. It is often integrated into broader management plans for patients experiencing chronic venous symptoms. By stabilizing the vascular walls and improving lymphatic drainage, the medication aims to improve the functional quality of life for individuals dealing with circulatory congestion.

Regulatory References

  1. WHO Collaborating Centre for Drug Statistics Methodology

What side effects are possible with Vasican?

Possible Side Effects and Safety Information

The safety profile of Vasican (Bromhexine hydrochloride) is classified by regulatory authorities based on the frequency and system-organ class affected. The vast majority of documented adverse reactions relate to the gastrointestinal system or hypersensitivity responses.

Category Examples of Officially Listed Adverse Reactions
Uncommon (Affects 1 to 10 in 1,000 users) Nausea, Vomiting, Diarrhoea, Upper abdominal pain.
Rare (Affects 1 to 10 in 10,000 users) Hypersensitivity reactions, Rash, Urticaria (Hives).
Not Known (Frequency cannot be estimated) Severe Cutaneous Adverse Reactions (SCARs), Anaphylactic Shock, Angioedema, Bronchospasm.

Serious adverse reactions are prominently documented in the official safety profile. These include the potential for Anaphylactic Shock and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Erythema multiforme. The development of SCARs may be preceded by non-specific, influenza-like prodromal symptoms, which is a documented safety pattern.

Specific population-based cautions are noted in the product information. Use requires caution in individuals with severe hepatic or renal impairment due to the potential for reduced drug clearance. Caution is also advised for patients with a history of gastroduodenal ulcers, and the medicine is generally not recommended for use during pregnancy or lactation. A specific safety constraint notes that co-administration with antitussives is generally avoided to prevent the accumulation of mucus, which runs contrary to the medicine’s intended action.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Vasican (Bromhexine hydrochloride) provides precise guidance on overdose manifestations and mandated emergency actions.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Symptoms are consistently reported as non-specific and are generally consistent with known side effects at recommended doses. Observed manifestations may include Nausea, Vomiting, Diarrhoea, and Upper abdominal pain.
Physiological systems affected Primary effects observed in overdose reports relate to the Gastrointestinal and Dermatologic systems.
Emergency-response statements Urgent medical advice must be sought immediately upon suspicion of overdose. Official instructions mandate the action to immediately contact a doctor, pharmacist, or the national Poisons Information Centre for guidance.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity classification Regulatory documents do not define a unique toxic dose level, focusing instead on the potential for severe hypersensitivity reactions, which require immediate medical intervention.
Overdose-context constraints No specific antidote is listed in the official prescribing information, and management is constrained to symptomatic and supportive treatment.

Resulting Overdose Structure

Official overdose statements:

  • Symptoms reported following accidental overdose are documented as being non-specific and typically consistent with the known side effect profile of the medicine.
  • Management is officially constrained to symptomatic and supportive treatment.

Connection to the overall overdose profile (2–4 sentences): The regulatory profile is structured around the immediate requirement to seek professional assistance, as clinical manifestations are non-specific and do not differentiate the event from a high dose or known side effects. This mandated immediate contact with emergency services enables the prompt administration of the officially described supportive care.

Therapeutic Uses of Vasican

What Vasican Treats: Main Uses and Benefits

Vasican (Bromhexine) is commonly used to help with symptomatic challenges defined by abnormal viscosity and excessive production of mucus within the lower airways. Its therapeutic benefit is applied across domains where additional symptomatic support is needed due to thick, tenacious phlegm. The medication is categorized as a mucolytic, and is relevant for easing symptoms related to chest congestion.


This medication is relevant for managing the symptomatic burden of conditions such as acute bronchitis, tracheobronchitis, and flares of seasonal respiratory infections. It provides supportive assistance for individuals with conditions characterized by periods of heightened symptoms related to chronic bronchopulmonary disorders, including COPD and bronchiectasis. The core benefit is applied in addressing symptoms related to difficult expectoration and persistent chest congestion.

In situations involving thick phlegm, the medication may assist with reducing the functional strain and effort required to cough. It assists with maintaining functional stability when secretions interfere with routine activities, contributing to improved comfort for both adults and children requiring assistance with phlegm removal.

Quick Fact

Property Description
Quick Fact: Supports Management of Ineffective Productive Cough
Symptom Targeted Difficulty in expelling thick, tenacious phlegm
Context of Use Acute episodes of bronchitis, chronic mucus disorders
Focus of Benefit Assists with maintaining functional stability

Regulatory References

  1. Australian Therapeutic Goods Administration (TGA) monograph

Eligibility and Restrictions for Use

Vasican (Bromhexine hydrochloride) eligibility is strictly defined by regulatory authorities based on age, physiological status, and underlying health conditions. This information reflects official population restrictions and contraindications only.

Contraindications

The medicine is strictly contraindicated for individuals who have a known hypersensitivity or allergic reaction to the active ingredient, bromhexine hydrochloride, or any of the product's inactive components. Treatment must also be immediately discontinued if the user experiences severe, progressive skin or mucosal lesions.

Age-Based and Conditional Restrictions

Vasican is generally approved for use in adults and adolescents aged 12 years and over. Use is typically not recommended for children under the age of six years, a restriction that may be lower in some regions. Special caution or medical supervision is required for patients with severe hepatic (liver) or renal (kidney) impairment, as these conditions can affect the clearance of the medicine. Individuals with a history of peptic or gastric ulceration should also use the medicine with caution.

Pregnancy and Lactation Status

Use is generally not recommended during the first trimester of pregnancy. Furthermore, the medicine is not recommended for use by breastfeeding mothers due to the potential for excretion of the substance into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for Vasican, based strictly on authoritative governmental regulatory information. The primary focus of interaction-related constraints for this product involves concurrent use with medicines that affect coagulation.


Officially Documented Interaction Profile

Interaction Domain Mechanism and Constraint
Drugs Affecting Coagulation Omega-3 acid ethyl esters, the active component of Vasican, may prolong bleeding time, increasing the potential for bleeding when co-administered with other medicines that inhibit platelet aggregation or affect coagulation.
Monitoring Requirement Patients who are receiving treatment with Vasican concurrently with drugs affecting coagulation, such as anti-platelet agents, require periodic monitoring by a healthcare professional.

Interaction Context

Regulatory documentation emphasizes that Vasican's potential to prolong bleeding time necessitates specific procedural constraints for its combined use with certain therapeutic classes. This is not a contraindication, but a clinically significant interaction requiring close observation. The official prescribing information requires that these patients be monitored periodically to assess for changes in bleeding parameters. The interaction profile is solely defined by this effect on coagulation and does not list any other specific drug-to-drug or product-to-product constraints in the official regulatory documentation.

Mechanism of Action

How Vasican Works — Mechanism of Action

Mucus Fluidization and Secretolytic Action

Vasican acts as a secretolytic agent primarily within the respiratory tract, modulating the seromucous glands. Its mechanism involves promoting the depolymerization of acid mucopolysaccharide fibers in bronchial secretions while simultaneously stimulating the synthesis of thinner, serous mucus. This biochemical modification reduces the viscosity and elasticity of the secretions, a required physical change for their subsequent propulsion from the airways.


Enhanced Mucociliary Clearance

In addition to mucus modification, Vasican exhibits a secretomotoric effect through the stimulation of the ciliary epithelium lining the airways. This action increases the frequency and velocity of ciliary beating, which physically accelerates the rate of mucociliary clearance. This facilitated transport of fluid secretions contributes to the potential for increased ease of expectoration.


Molecular Enzyme Inhibition

As a distinct molecular action, Vasican operates as an inhibitor of the cell-surface protease, Transmembrane Protease Serine 2 ( TMPRSS2). This interference modulates a specific pathway involved in protein processing, contributing to the overall mechanistic profile within the respiratory system.

Dosage and Administration Information

How to Use Vasican

Vasican (Bromhexine hydrochloride) is administered via the oral route, consistent with its primary forms being tablets and aqueous solutions or syrups. The drug's usage is defined by specific quantitative and temporal patterns.


Dosing Regimen

The standard frequency for this medicine is three times per day (t.d.s.). Standard dosing regimens include:

Population Standard Daily Dosage Pattern Maximum Daily Dose (Short-Term)
Adults and Adolescents (ge 12 years) 8 mg administered t.d.s. 48 mg/day (only for the first 7 days)
Children 6-11 years 8 mg administered t.d.s. Not to exceed 24 mg/day

For oral solutions, a calibrated measuring device must be used to ensure the precise volume for the required dosage is taken.

Administration Conditions and Course Duration

Vasican can be taken with or without food, as there is no specified requirement for meal consumption relative to administration. The medicine is intended for short-term use, and the treatment course should not exceed seven consecutive days unless otherwise advised by a health professional. In cases of severe renal or hepatic insufficiency, there is a potential for reduced clearance, which constitutes a special condition for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vasican


Evidence for Acute Symptoms of Respiratory Infection

Research has studied Vasican for managing the short-term symptoms of acute respiratory illnesses, such as acute bronchitis or seasonal flares, where individuals experience persistent chest congestion due to thick mucus. Studies examined patients with conditions associated with acute or disruptive episodes. In these settings, researchers monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Studies monitored changes in patient-reported ease of expectoration in the short term. These findings describe patterns observed in the studies related to mucoactive properties. The existing evidence base is often evaluated alongside data from other structurally similar mucoactive agents. Research so far provides context on short-term symptom changes but evidence is limited on whether the medicine affects the overall resolution time of the underlying infection itself.


Research into Chronic Bronchopulmonary Conditions

Vasican was studied in research contexts involving conditions characterized by periods of heightened symptoms, such as Chronic Bronchitis and the symptomatic management of COPD. Research in this area includes both foundational clinical trials and comprehensive systematic reviews and meta-analyses. The research examined adult populations experiencing fluctuating or unstable symptoms related to mucus hypersecretion.

In some longer-term studies, research investigated whether there were patterns related to the frequency of exacerbations and functional measures. Findings describe patterns observed in the studies related to symptom patterns during periods of increased symptom activity. The research examining Vasican in these chronic conditions often includes studies that were designed using earlier methodological standards, and the evidence quality varies across studies.


Key Research Gaps and Uncertainties

Research describes Vasican as a mucoactive agent, but the original studies were conducted before current, rigorous methodological standards were widely adopted. For chronic conditions, the certainty remains low regarding the long-term impact on major clinical events, such as the sustained prevention of exacerbations. Comparative evidence against other mucoactive therapies is limited. While research provides context, it does not determine whether an individual will respond similarly, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Bromhexine For Acute Bronchitis: a Systematic Review (Review on acute symptom reduction)
  2. Australian Product Information – Bisolvon® Chesty (Bromhexine Hydrochloride) (Regulatory document and product monograph)
  3. Bromhexine Hydrochloride: Potential Approach to Prevent or Treat Early Stage Novel 2019 Coronavirus Disease (Provides context on special populations and emerging research)

Frequently Asked Questions (FAQ)

Common questions about Vasican (FAQ)

Q: Does Vasican only treat the symptoms, or does it affect the underlying condition?

A: Vasican acts as a mucoactive agent, and official research has primarily focused on its role in alleviating symptoms like thick mucus and congestion. Studies indicate that the medicine helps the body clear the airways. Evidence is described as limited on whether the medicine affects the overall time it takes for an underlying infection to resolve.


Q: How does Vasican compare to other similar medications people talk about?

A: The regulatory body reviews indicate that comparative evidence against other mucoactive therapies is limited. Research findings are often evaluated alongside data from drugs with a structurally similar mechanism of action. Official documents do not make claims of superiority or inferiority compared to other medicines.


Q: Does Vasican interact with common pain relievers like ibuprofen?

A: The official interaction profile states that Vasican may prolong bleeding time. Because of this, when taken with other medicines that inhibit platelet aggregation—which includes certain common pain relievers—there is an increased potential for bleeding.


Q: How is the benefit of Vasican typically measured by doctors?

A: In clinical studies, researchers measured outcomes related to physical discomfort and changes in patient-reported ease of expectoration (the ease of coughing up phlegm). These measurements provide context on how the medicine affects short-term symptom relief, rather than long-term clinical outcomes.


Q: What is the difference between how Vasican works and how similar drugs work?

A: Vasican is formally classified as a mucolytic and secretolytic agent. Its primary actions are breaking down thick mucus fibers and stimulating ciliary activity in the lungs to clear the airways. This mechanism distinguishes it from cough suppressants, which act on the brain to stop the urge to cough.


Q: Why do official documents list so many potential side effects for Vasican?

A: Official documents list all adverse reactions reported by frequency (such as Uncommon, Rare, or Not Known) in accordance with regulatory reporting standards. These standards are designed to capture all known reactions from clinical trials and post-marketing surveillance to inform patients comprehensively about what has been observed.


Q: Does Vasican help improve quality of life, not just clinical measures?

A: Studies have monitored patient-reported outcomes, which are subjective measures of improvement, alongside objective clinical measures. This includes descriptive data related to perceived discomfort and overall symptomatic improvement, which can relate to quality of life.


Q: What should I know about drug interactions involving Vasican and common cold medicines?

A: Official safety constraints note that taking Vasican with antitussive (cough-suppressing) medicines is generally avoided. This is because suppressing the cough reflex runs contrary to Vasican's intended action of helping the body remove accumulated mucus.


Q: Are there any specific warnings about using Vasican before a planned surgery?

A: Official documentation notes the drug has the potential to prolong bleeding time when co-administered with medicines that affect coagulation. This specific profile may necessitate caution or medical supervision before any planned surgical or dental procedure.


Q: How quickly does Vasican start to have an effect?

A: Following oral administration, the substance typically reaches its peak concentration in the bloodstream within 30 minutes to 1 hour. Clinical effects related to mucus changes are often cited as becoming noticeable after 2 to 3 days of use.


Q: What happens if I miss a dose of Vasican?

A: Official administration instructions state that if a dose is missed, it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance is to skip the missed dose and avoid taking two doses at the same time.


Q: Is it common to feel tired when starting Vasican?

A: The official safety profile lists dizziness and headache as reported adverse effects. Other nervous system effects, such as sleepiness or feeling lightheaded, have been reported in some contexts. Generalized 'tiredness' is not a universally listed primary side effect.


Q: Does Vasican contain any common allergens like gluten or lactose?

A: Hypersensitivity to any inactive component (excipient) in the medicine is listed as a contraindication. The specific list of excipients, such as gluten or lactose, can vary by the exact product form and is detailed in the regulatory leaflet for that specific product.


Q: How long does the effect of Vasican last after the last dose?

A: The duration of the drug in the body is described by its elimination half-life, which is the time it takes for half of the substance to be removed. Official documentation reports this terminal elimination half-life to range between 6.6 and 31.4 hours.


Q: Is Vasican considered safe for older adults?

A: The standard safety information applies to the general adult population, and no specific warnings are mandated solely based on age. Official documentation notes that special caution or medical supervision may be applicable if the individual has underlying conditions such as severe kidney or liver impairment.


Q: Are there any lab tests required before or during treatment with Vasican?

A: Periodic monitoring by a healthcare professional is noted as necessary in official documents for individuals taking Vasican concurrently with other drugs that affect blood coagulation. This monitoring is required to assess for changes in bleeding parameters.


Q: Does using alcohol affect how Vasican works?

A: Official safety information may contain a cautionary note regarding the consumption of alcohol. This is because alcohol use may increase the nervous system side effects of the medicine, such as dizziness or drowsiness.


Q: Is Vasican available as a generic drug?

A: The active ingredient in Vasican is Bromhexine hydrochloride, which is the internationally established generic name for this compound. The generic substance is available in many formulations sold under various brand names across the world.


Q: Does Vasican affect my ability to drive or operate machinery?

A: Official safety advice recommends not operating machinery or driving if you experience dizziness or drowsiness while taking the medicine. Some regulatory sources note that specific studies on this effect have not been performed.


Q: If I have a mild reaction, is that considered a reason to stop using Vasican?

A: Official safety warnings require immediate discontinuation of treatment if severe, progressive skin or mucosal lesions (SCARs) occur. Guidance for managing or stopping treatment due to mild reactions is not explicitly defined in the official warnings, which prioritize life-threatening events.


Q: Are there different strengths of Vasican available?

A: Yes, according to the official product information, Vasican is available in multiple dosage forms, including tablets, syrups, and oral solutions. These forms are available in different corresponding strengths and concentrations as defined by regional regulatory approvals.


Q: Is a prescription required to get Vasican?

A: The status of the drug is defined by regional regulatory authorities. In certain regions, it is classified as a pharmacy-only medicine, while in others, it is categorized as a prescription-only medicine.


Q: Is it normal to not feel any different after starting Vasican?

A: Yes, the onset of the medicine's clinical effect is generally observed after 2 to 3 days of use. Due to this delay, an immediate or drastic change in symptoms after the first few doses is not the expected pattern.

How should Vasican be stored and disposed of?

Official Storage and Disposal Instructions for Vasican

Storage of Vasican (Bromhexine hydrochloride) must strictly adhere to the conditions mandated in official regulatory documents to maintain its stability and shelf life.

Storage Requirements

Condition Regulatory Requirement
Temperature Store below 30 C or 25 C, as specified on the label. Do not store above the maximum defined temperature.
Protection Keep the medicine inside the outer carton to protect the contents from light.
Container Must be stored in the original container. Syrup bottles require a child-proof cap.
Child Safety Keep out of the sight and reach of children at all times.

Disposal

Unused or expired Vasican must be disposed of in accordance with local requirements for pharmaceutical waste. Do not discard the product via household wastewater or general trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasican found in:

A-Z Index: